Legacy public health communication on general health and science topics has long emphasized broad wellness principles, such as balanced nutrition, routine screening, and avoidance of known carcinogens like tobacco. This foundational approach provides a framework for understanding disease prevention, yet it often remains at a population level, leaving individuals to navigate specific personal risk factors on their own. As health information evolves, there is a growing need to translate these general principles into actionable guidance for those facing particular exposures. In the context of occupational settings, workers may encounter substances that shift the focus from universal advice to targeted risk assessment. This transition is especially relevant when considering the long-term outcomes associated with certain therapeutic agents and their potential links to rare malignancies.
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has received regulatory approval in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication and is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).
Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab and pembrolizumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who become refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). Retrospective studies have evaluated the combination of ipilimumab plus nivolumab in avelumab-refractory MCC. In one study conducted at three academic sites in Germany, three out of five patients with metastatic MCC refractory to avelumab responded to combined ipilimumab plus nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A larger multicenter study from the prospective skin cancer registry ADOREG confirmed that immune checkpoint inhibition has improved outcomes in metastatic MCC, but data on avelumab-refractory patients remain limited (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study noted that despite the clinical benefit of immune checkpoint inhibitors, approximately 50% of patients with advanced MCC progress on therapy, underscoring the need for alternative strategies (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Avelumab is known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab; the hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case highlights the potential for avelumab to trigger or exacerbate underlying immune-mediated conditions, which may complicate prognosis and management. Regarding the adequacy of warnings, the available evidence indicates that avelumab's approval and clinical use are supported by trial data showing efficacy in a subset of patients, but the risk of progression remains substantial. The prescribing information for avelumab includes warnings about immune-related adverse events, but the specific risk of progression in avelumab-refractory MCC is not explicitly addressed in the provided evidence. The timeline between avelumab exposure and documented harm is variable: immune-related adverse events can occur during treatment, as in the sarcoidosis case (https://pubmed.ncbi.nlm.nih.gov/31543781/), while progression may be observed after initial response or as primary resistance. The evidence does not provide a precise latency period for progression or adverse events.
Prognosis-related considerations for affected patients are significant. MCC is an aggressive malignancy with poor prognosis, and while avelumab offers durable responses in some patients, approximately half will progress (https://pubmed.ncbi.nlm.nih.gov/35877101/). For those who progress on avelumab, alternative therapies such as ipilimumab plus nivolumab may provide benefit, but data are limited to small retrospective series (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). The prognosis for avelumab-refractory patients remains guarded, and further research is needed to identify predictive biomarkers and optimal sequencing of therapies. In summary, avelumab is an established treatment for metastatic MCC with a demonstrated response rate, but a significant proportion of patients do not respond or eventually progress. Immune-related adverse events, including rare events like sarcoidosis reactivation, can occur during treatment. The timeline from exposure to harm is not well-defined in the evidence, and prognosis for avelumab-refractory patients is poor, with limited effective options.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved for the treatment of metastatic Merkel cell carcinoma (MCC) based on the JAVELIN Merkel 200 trial, which showed objective responses in about one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/).
While Avelumab can provide durable responses in some patients, approximately 50% of patients with advanced MCC progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For those who become refractory to Avelumab, treatment options are limited, though combination therapy with ipilimumab plus nivolumab has shown some benefit in small retrospective studies (https://pubmed.ncbi.nlm.nih.gov/33439294/). The prognosis for avelumab-refractory patients remains poor.
Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case involved hypercalcemia secondary to reactivation of sarcoidosis, which was managed with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other irAEs may occur, and patients should be monitored closely during treatment.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Free and confidential. No obligation — an initial records screening only.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.